Studies on Curaxin CBL0137 in preclinical models of pancreatic cancer
Cleveland BioLabs, Inc. and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the ...
Nov 14, 2014
0
0